The effect of soy isoflavones on non-alcoholic fatty liver disease and the level of fibroblast growth factor-21 and fetuin A

Asal Neshatbini Tehrani,Behzad Hatami,Bizhan Helli,Zahra Yari,Ghazal Daftari,Amin Salehpour,Mehdi Hedayati,Elmira Khalili,Seyed Ahmad Hosseini,Azita Hekmatdoost
DOI: https://doi.org/10.1038/s41598-024-55747-6
IF: 4.6
2024-03-02
Scientific Reports
Abstract:A two-arm randomized open labeled controlled clinical trial was conducted on 50 patients with non-alcoholic fatty liver disease (NAFLD). Subjects were randomized to either receive two tablets of soy isoflavone (100 mg/day) or placebo. At week 12, the serum levels of alanine amino transferase (ALT), aspartate amino transferase (AST) and controlled attenuation parameter (CAP) score were significantly decreased only in the soy isoflavone group (P < 0.05). A significant decline in the gamma glutamyl transferase (GGT) level was observed only in the placebo group (P = 0.017). A significant increase in the serum level of fetuin A was shown in both groups at the end of the trial with a significantly greater increment in the soy isoflavone group compared to the placebo group (P < 0.05). The changes in the serum level of FGF-21 were not significant in any of the two groups. Steatosis grade significantly improved only in the soy isoflavone group (P = 0.045). There was no significant change in the fibrosis grade in the groups. Soy isoflavone intake led to a decrease in ALT, AST, CAP score, steatosis grade and an increase in the level of fetuin A. However, no significant changes were observed in the fibrosis grade and serum levels of GGT and FGF-21.
multidisciplinary sciences
What problem does this paper attempt to address?
This paper attempts to address the management of non - alcoholic fatty liver disease (NAFLD), especially to evaluate the effect of soy isoflavones on patients with NAFLD. Specifically, the study aims to explore the effect of soy isoflavones on liver enzyme levels, fibroblast growth factor - 21 (FGF - 21) and fetuin A serum levels in patients with NAFLD, as well as the improvement effect on the degree of hepatic steatosis and fibrosis. ### Research Background Non - alcoholic fatty liver disease (NAFLD) is an increasingly serious health problem worldwide, characterized by the accumulation of fat in liver cells, which may lead to fibrosis, cirrhosis or hepatocellular carcinoma. The incidence of NAFLD is affected by factors such as age, geographical area and gender, and the estimated incidence in the general population is 15% - 30%. Lifestyle and diet adjustment are important strategies for the treatment of NAFLD, but the compliance rate is usually low and the effect of drug intervention is not satisfactory. Some studies have shown that some bioactive and functional dietary compounds can provide a synergistic effect when combined with lifestyle intervention, which is helpful for the treatment of NAFLD. Soy isoflavones, a component similar to estrogen but non - steroidal, exist in legumes and may have an inhibitory effect on the progression of NAFLD. ### Research Objectives The main objective of this study is to evaluate the effect of soy isoflavones on the management of NAFLD, especially on liver enzyme levels, FGF - 21 and fetuin A serum levels. Secondary objectives include evaluating the effect of soy isoflavones on anthropometric parameters such as body weight, waist circumference and hip circumference. ### Main Findings - **Liver Enzyme Levels**: Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and controlled attenuation parameter (CAP) scores in the soy isoflavone group were significantly decreased. - **Fetuin A**: The fetuin A serum levels in both groups were significantly increased, but the increase in the soy isoflavone group was greater. - **Steatosis**: A significant improvement in the steatosis grade was only observed in the soy isoflavone group. - **Fibrosis**: There was no significant change in the fibrosis grade in both groups. ### Conclusion The research results show that a daily intake of 100 mg of soy isoflavones, combined with lifestyle adjustment, has a positive impact on the treatment of NAFLD, especially in reducing liver enzyme levels and improving steatosis. However, soy isoflavones have no significant impact on the fibrosis grade. These findings provide a scientific basis for further research on the application of soy isoflavones in the management of NAFLD.